Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study
Latest Information Update: 28 Feb 2020
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms REGOTAS
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium
- 21 Jan 2020 According to a Bayer media release, data from this trial will be presented at 2020 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium, taking place January 23-25 in San Francisco, California
- 04 Jul 2017 Status changed from recruiting to completed.